AR096040A1 - Compuestos sustituidos y condensados de pirimidina como inhibidores de pde4b - Google Patents
Compuestos sustituidos y condensados de pirimidina como inhibidores de pde4bInfo
- Publication number
- AR096040A1 AR096040A1 ARP140101599A ARP140101599A AR096040A1 AR 096040 A1 AR096040 A1 AR 096040A1 AR P140101599 A ARP140101599 A AR P140101599A AR P140101599 A ARP140101599 A AR P140101599A AR 096040 A1 AR096040 A1 AR 096040A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- substituted
- branched
- single chain
- alkoxy
- Prior art date
Links
- 101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 title 1
- 102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 17
- 125000000217 alkyl group Chemical group 0.000 abstract 10
- 125000002947 alkylene group Chemical group 0.000 abstract 6
- -1 cyano, carboxyl Chemical group 0.000 abstract 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 5
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 4
- 125000004450 alkenylene group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 125000003636 chemical group Chemical group 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 125000006590 (C2-C6) alkenylene group Chemical group 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 101100516554 Caenorhabditis elegans nhr-5 gene Chemical group 0.000 abstract 1
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Sus usos como medicamentos, en particular como medicamentos para el tratamiento de condiciones y enfermedades que pueden ser tratadas por la inhibición de la enzima PDE4. Reivindicación 1: Compuestos de pirimidina de fórmula general (1) caracterizados porque G es un fenilo opcionalmente sustituido con al menos un sustituyente Z o un heterociclo aromático de 5 ó 6 miembros opcionalmente sustituido con al menos un sustituyente Z, en donde dicho fenilo o heterociclo aromático puede estar condensado con un anillo de 4, 5, 6 ó 7 miembros, en donde dicho anillo condensado puede estar saturado, parcialmente insaturado o ser aromático y puede estar sustituido con al menos un sustituyente Z; Z independientemente uno del otro es alquilo C₁₋₆, hidroxialquilo C₁₋₆, alcoxi C₁₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, alquilo -SC₁₋₆, halógeno, hidroxilo o ciano o es alquilo SO₂C₁₋₆, CONH₂, alquilo NHSO₂C₁₋₆, alquilo NHCOC₁₋₆, en donde los mencionados alquilos están ramificados o en cadena única y pueden ser sustituidos; T es CR¹R² o S(O)ˣ o S(O)=NH; x es 0, 1 ó 2; R¹ y R² independientemente uno del otro denotan hidrógeno, alquilo C₁₋₆, alcoxi C₁₋₆, haloalquilo C₁₋₆, halógeno, hidroxilo o ciano, en donde los mencionados alquilos están ramificados o en cadena única y pueden ser sustituidos; n es 1 ó 2; K es alquilo C₁₋₆, alcoxi C₁₋₆, haloalquilo C₁₋₆, halógeno, hidroxilo o ciano, en donde los mencionados alquilos están ramificados o en cadena única y pueden ser sustituidos; y m es 0, 1, 2, 3 ó 4; X independientemente uno del otro es un alquilo C₁₋₆, cicloalquilo C₃₋₆, alcoxi C₁₋₆, cicloalcoxi C₃₋₆, haloalquilo C₁₋₆, haloalcoxi C₁₋₆, halógeno, hidroxilo, ciano, carboxilo, C(O)-NH₂, alquilo C(O)-NH-C₁₋₆, C₍O₎₋N₍ₐₗqᵘⁱₗₒ C₁₋₆)₂, NH₂, alquilo NH-C₁₋₆, N(alquilo C₁₋₆)₂, N-pirrolidinil, N-piperidinil, N-morfolinil, NH-CHO, alquilo NH-C(O)-C₁₋₆, alquilo S(O)₂-NH₂, alquilo S-C₁₋₆, alquilo S(O)-C₁₋₆, alquilo S(O)₂-C₁₋₆, O-alquilo C₁₋₄-CN, O-alquilo C₁₋₄-NH-CHO, O-alquilo C₁₋₄-NH-C(O)-alquilo C₁₋₆, ó O-alquilo C₁₋₄-N(alquilo C₁₋₆)₂, o es O-alquilo C₁₋₄-O-alquilo C₁₋₄, en donde las mencionadas cadenas están ramificadas o en cadena única y pueden ser sustituidas, o es un grupo químico L-CO₂R³ o O-alquilo C₁₋₄-CO-R⁴ (preferentemente O-CH₂-COR⁴) o LCONR⁴; R³ es hidrógeno, alquilo C₁₋₆ ramificado o en cadena única; R⁴ es NH₂, NHR⁵, NR⁵R⁶, alcoxi C₁₋₆; R⁵ y R⁶ independientemente uno del otro es alquilo C₁₋₆, hidroxialquilo C₁₋₆, cicloalquilo C₃₋₆, alquilo C₁₋₆cicloalquilo C₃₋₆, heterocicloalquilo C₃₋₆, o R⁵ y R⁶ junto con el átomo de nitrógeno al cual están unidos forman un heterociclo saturado de 3 a 6 miembros, opcionalmente sustituido con alquilo C₁₋₆ ramificados o en cadena única o con grupos hidroxilo, en los cuales los mencionados heterociclos pueden opcionalmente tener un heteroátomo más seleccionado de O, S, y N; L es un enlace, alquileno C₁₋₆, alquenileno C₂₋₆, alquileno -O-C₁₋₄, alquileno -NH-C₁₋₄, o alquileno -NR³-C₁₋₄, en donde los mencionados alquilenos o alquenilenos pueden cada uno ser sustituidos con uno o más átomos halógenos (en particular flúor) o en donde los mencionados alquilenos o alquenilenos pueden ser sustituidos con uno o más grupos alquilo C₁₋₆, preferentemente metilo o etilo, o en donde los mencionados alquilenos o alquenilenos una unidad CH₂ puede ser reemplazada por un átomo de oxígeno; p es 1, 2, 3 ó 4; U~V es un grupo químico en donde ~ se refiere a un enlace simple o doble, U se refiere a un átomo de carbono sustituido o no sustituido, un átomo de nitrógeno sustituido o no sustituido o un grupo carbonilo, y V se refiere a un átomo de carbono sustituido o no sustituido, un átomo de nitrógeno sustituido o no sustituido, o un átomo de oxígeno; así como también las sales, diasterómeros, enantiómeros, racematos, hidratos o solvatos que sean farmacológicamente tolerables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13001993 | 2013-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR096040A1 true AR096040A1 (es) | 2015-12-02 |
Family
ID=48141722
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101599A AR096040A1 (es) | 2013-04-16 | 2014-04-15 | Compuestos sustituidos y condensados de pirimidina como inhibidores de pde4b |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9527832B2 (es) |
| EP (1) | EP2986600B1 (es) |
| JP (1) | JP2016516787A (es) |
| AR (1) | AR096040A1 (es) |
| AU (1) | AU2014253810A1 (es) |
| BR (1) | BR112015026055A2 (es) |
| CA (1) | CA2909464A1 (es) |
| ES (1) | ES2642822T3 (es) |
| HU (1) | HUE034254T2 (es) |
| MX (1) | MX2015013936A (es) |
| PL (1) | PL2986600T3 (es) |
| TW (1) | TW201512189A (es) |
| WO (1) | WO2014170020A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR101196A1 (es) * | 2014-07-16 | 2016-11-30 | Gruenenthal Gmbh | Compuestos de pirimidina sustituidos |
| AR101197A1 (es) | 2014-07-16 | 2016-11-30 | Gruenenthal Gmbh | Pirimidinas 2,5-sustituidas |
| AR101198A1 (es) | 2014-07-16 | 2016-11-30 | Gruenenthal Gmbh | Pirimidinas 2,5-sustituidas como inhibidores de pde4b |
| AR107099A1 (es) * | 2015-12-22 | 2018-03-21 | Gruenenthal Gmbh | Compuestos espiro-[indolin heterocicloalcano] como inhibidores de la fosfodiesterasa |
| JP2020505399A (ja) * | 2017-01-25 | 2020-02-20 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 化合物 |
| JP2020506966A (ja) * | 2017-01-25 | 2020-03-05 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 化合物 |
| CN109761809A (zh) * | 2019-02-16 | 2019-05-17 | 安徽华胜医药科技有限公司 | 一种钯碳催化还原合成2-溴-2-(2-氟-3-甲氧基苯基)乙酸乙酯的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1238149A (en) | 1984-10-30 | 1988-06-14 | Jacynthe Cote | Closed cell phenolic foams |
| SI0706513T1 (en) | 1993-07-02 | 2002-10-31 | Altana Pharma Ag | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
| KR20060118398A (ko) | 2003-08-05 | 2006-11-23 | 버텍스 파마슈티칼스 인코포레이티드 | 전압 개폐 이온 채널 억제제로서의 축합 피라미딘 화합물 |
| TW200621257A (en) | 2004-10-20 | 2006-07-01 | Astellas Pharma Inc | Pyrimidine derivative fused with nonaromatic ring |
| US20060293343A1 (en) | 2005-05-18 | 2006-12-28 | Asahi Kasei Pharma Corporation | Pyrimidine derivatives |
| US8486948B2 (en) * | 2007-10-19 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Piperazinodihydrothienopyrimidine derivatives |
| EP2951173B1 (en) * | 2013-02-04 | 2017-05-17 | Grünenthal GmbH | Novel substituted condensed pyrimidine compounds |
-
2014
- 2014-04-02 TW TW103112249A patent/TW201512189A/zh unknown
- 2014-04-15 JP JP2016508039A patent/JP2016516787A/ja active Pending
- 2014-04-15 AU AU2014253810A patent/AU2014253810A1/en not_active Abandoned
- 2014-04-15 BR BR112015026055A patent/BR112015026055A2/pt not_active Application Discontinuation
- 2014-04-15 CA CA2909464A patent/CA2909464A1/en not_active Abandoned
- 2014-04-15 EP EP14718916.1A patent/EP2986600B1/en not_active Not-in-force
- 2014-04-15 PL PL14718916T patent/PL2986600T3/pl unknown
- 2014-04-15 MX MX2015013936A patent/MX2015013936A/es unknown
- 2014-04-15 ES ES14718916.1T patent/ES2642822T3/es active Active
- 2014-04-15 WO PCT/EP2014/001013 patent/WO2014170020A1/en not_active Ceased
- 2014-04-15 AR ARP140101599A patent/AR096040A1/es unknown
- 2014-04-15 HU HUE14718916A patent/HUE034254T2/en unknown
-
2015
- 2015-10-15 US US14/883,986 patent/US9527832B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20160031857A1 (en) | 2016-02-04 |
| JP2016516787A (ja) | 2016-06-09 |
| PL2986600T3 (pl) | 2017-12-29 |
| US9527832B2 (en) | 2016-12-27 |
| MX2015013936A (es) | 2015-12-11 |
| WO2014170020A1 (en) | 2014-10-23 |
| CA2909464A1 (en) | 2014-10-23 |
| BR112015026055A2 (pt) | 2017-07-25 |
| EP2986600B1 (en) | 2017-07-05 |
| TW201512189A (zh) | 2015-04-01 |
| HUE034254T2 (en) | 2018-02-28 |
| ES2642822T3 (es) | 2017-11-20 |
| AU2014253810A1 (en) | 2015-12-03 |
| EP2986600A1 (en) | 2016-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR096040A1 (es) | Compuestos sustituidos y condensados de pirimidina como inhibidores de pde4b | |
| AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
| AR088829A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
| AR114164A1 (es) | Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| AR106472A1 (es) | Inhibidores de acc y usos de los mismos | |
| PE20142164A1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| AR075975A1 (es) | Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3 | |
| AR101198A1 (es) | Pirimidinas 2,5-sustituidas como inhibidores de pde4b | |
| PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
| AR108388A2 (es) | Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
| AR090760A1 (es) | Compuestos de benzotiazol y su uso contra el virus de hiv | |
| EA201390163A1 (ru) | Гетеробициклические производные в качетстве ингибиторов hcv | |
| CR20170118A (es) | Derivados espirodiamina como inhibidores de la aldosterona sintasa | |
| AR082914A1 (es) | Heteroarilmetilamidas utiles para tratar enfermedades cardiovasculares y dislipemias, composiciones farmaceuticas que las contienen y proceso de preparacion de los mismos | |
| BR112016019462B8 (pt) | Compostos heterocïclicos tricïclicos como inibidores de fosfoinosotida 3-cinase | |
| AR094812A1 (es) | Derivado de piridina monocíclico como inhibidor del fgfr | |
| UY30104A1 (es) | Derivados nuevos de urea ciclica, su preparacinn y su utilizacinn farmacéutica como inhibidores de cinasas | |
| AR095351A1 (es) | Inhibidores de histona desacetilasa (hdac) | |
| AR064729A1 (es) | Derivados de 2,4-dianilinopirimidinas, su preparacion, composiciones farmaceuticas y usos como inhibidores de ikk | |
| AR111307A1 (es) | Derivados de 1,2-dihidroespiro[ciclohexan-1,3-indol] o 1,2-dihidroespiro[ciclohexan-1,3-pirrolo[3,2-b]piridina] como inhibidores de hexakisfosfato quinasa | |
| AR101197A1 (es) | Pirimidinas 2,5-sustituidas | |
| AR102825A1 (es) | Derivados heterocíclicos de amida activos como plaguicidas con sustituyentes que contienen azufre |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |